MCID: CHR176
MIFTS: 24

Chromophil Renal Cell Carcinoma

Categories: Cancer diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Chromophil Renal Cell Carcinoma

MalaCards integrated aliases for Chromophil Renal Cell Carcinoma:

Name: Chromophil Renal Cell Carcinoma 53
Papillary Renal Cell Carcinoma 73
Chromophil Rcc 53

Classifications:



External Ids:

UMLS 73 C1306837

Summaries for Chromophil Renal Cell Carcinoma

MalaCards based summary : Chromophil Renal Cell Carcinoma, also known as papillary renal cell carcinoma, is related to renal cell carcinoma, papillary, 1 and renal cell carcinoma, nonpapillary, and has symptoms including flank pain The drugs Sunitinib and Sorafenib have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and thyroid.

Related Diseases for Chromophil Renal Cell Carcinoma

Diseases related to Chromophil Renal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, papillary, 1 11.4
2 renal cell carcinoma, nonpapillary 10.6

Symptoms & Phenotypes for Chromophil Renal Cell Carcinoma

UMLS symptoms related to Chromophil Renal Cell Carcinoma:


flank pain

Drugs & Therapeutics for Chromophil Renal Cell Carcinoma

Drugs for Chromophil Renal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 3,Phase 2 557795-19-4, 341031-54-7 5329102
2
Sorafenib Approved, Investigational Phase 3,Phase 1,Phase 2 284461-73-0 216239 406563
3
Everolimus Approved Phase 3,Phase 2 159351-69-6 6442177
4
Sirolimus Approved, Investigational Phase 3,Phase 2 53123-88-9 46835353 6436030 5284616
5
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
6 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
7 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
8 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
9 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
10 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
11 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
12 Antifungal Agents Phase 3,Phase 2,Phase 1,Not Applicable
13 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
14 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
15
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
16
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
17
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
18
Gemcitabine Approved Phase 2 95058-81-4 60750
19
Fludarabine Approved Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
20
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
21
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
22
leucovorin Approved Phase 2 58-05-9 6006 143
23
Lenograstim Approved, Investigational Phase 2 135968-09-1
24
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
25
Nicotinamide Approved, Investigational Phase 1, Phase 2,Phase 2 98-92-0 936
26
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
27
Dactinomycin Approved, Investigational Phase 2 50-76-0 457193 2019
28
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
29
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
30
Etoposide Approved Phase 2 33419-42-0 36462
31
Metformin Approved Phase 1, Phase 2 657-24-9 14219 4091
32
Nivolumab Approved Phase 2 946414-94-4
33
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
34
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
35
Vidarabine Approved, Investigational Phase 1, Phase 2,Phase 2,Not Applicable 24356-66-9 32326 21704
36
Mycophenolic acid Approved Phase 1, Phase 2,Phase 2,Not Applicable 24280-93-1 446541
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
38
Niacin Approved, Investigational, Nutraceutical Phase 1, Phase 2,Phase 2 59-67-6 938
39
Camptothecin Experimental Phase 2 7689-03-4
40
Doxil Approved June 1999 Phase 2 31703
41
Lactitol Investigational Phase 2 585-86-4 3871
42
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
43 Mitogens Phase 2
44 Immunoglobulin G Phase 2
45 Antibodies Phase 2,Phase 1
46 Antibodies, Monoclonal Phase 2
47 Endothelial Growth Factors Phase 2
48 Immunoglobulins Phase 2,Phase 1
49 Antimetabolites Phase 2,Phase 1,Not Applicable
50 Antineoplastic Agents, Phytogenic Phase 2

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer Completed NCT00492258 Phase 3 sorafenib tosylate
2 Savolitinib vs. Sunitinib in MET-driven PRCC Active, not recruiting NCT03091192 Phase 3 Savolitinib;Sunitinib
3 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Active, not recruiting NCT01120249 Phase 3 everolimus
4 Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer Unknown status NCT00541008 Phase 2 sunitinib malate
5 A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) Completed NCT00726323 Phase 2 foretinib (formerly GSK1363089 or XL880)
6 Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery Completed NCT01688973 Phase 2 Erlotinib Hydrochloride;Tivantinib
7 Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer Completed NCT00060307 Phase 2 erlotinib hydrochloride
8 Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer Completed NCT00459875 Phase 2 sunitinib malate
9 RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe Completed NCT00688753 Phase 2 RAD001
10 Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors Completed NCT00605618 Phase 1, Phase 2 BMS-777607
11 Bortezomib in Treating Patients With Metastatic Kidney Cancer Completed NCT00276614 Phase 2 bortezomib
12 Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer Completed NCT01727089 Phase 2
13 Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer Completed NCT00401128 Phase 2 gemcitabine hydrochloride;irinotecan hydrochloride
14 Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery Completed NCT00459979 Phase 2 sunitinib malate
15 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer Completed NCT00027573 Phase 2 cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
16 Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer Completed NCT00126503 Phase 1, Phase 2 Sorafenib Tosylate
17 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Completed NCT00335556 Phase 2 Doxorubicin Hydrochloride;Irinotecan Hydrochloride;Cyclophosphamide;Etoposide;Carboplatin;Vincristine Sulfate
18 A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer Recruiting NCT02019693 Phase 2 INC280
19 Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma Recruiting NCT02495103 Phase 1, Phase 2 Vandetanib;Metformin;Vandetanib/Metformin
20 A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer Recruiting NCT01130519 Phase 2 Bevacizumab;Erlotinib
21 Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) Recruiting NCT03177239 Phase 2 Nivolumab;Ipilimumab
22 A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) Active, not recruiting NCT02127710 Phase 2 AZD6094
23 Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma Active, not recruiting NCT02489695 Phase 2 axitinib
24 CREATE: Cross-tumoral Phase 2 With Crizotinib Active, not recruiting NCT01524926 Phase 2 Crizotinib (PF-02341066)
25 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Active, not recruiting NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
26 Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer Active, not recruiting NCT00027820 Phase 1, Phase 2 Fludarabine Phosphate;Cyclosporine;Mycophenolate Mofetil
27 Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery Active, not recruiting NCT01164228 Phase 2 gemcitabine hydrochloride;sunitinib malate
28 Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Active, not recruiting NCT01767636 Phase 2 Pazopanib Hydrochloride
29 ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) Not yet recruiting NCT03685448 Phase 2 Cabozantinib
30 Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Suspended NCT02761057 Phase 2 Cabozantinib S-malate;Crizotinib;Savolitinib;Sunitinib Malate
31 Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer Terminated NCT00601926 Phase 2
32 Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer Terminated NCT00323791 Phase 2 gemcitabine hydrochloride;imatinib mesylate
33 Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Terminated NCT00098618 Phase 2 sorafenib tosylate
34 First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b Recruiting NCT03319628 Phase 1 XMT-1536
35 HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma Terminated NCT02947152 Phase 1 HKT288
36 A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma Terminated NCT02837991 Phase 1 CDX-014
37 DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE Completed NCT00900536
38 Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer Active, not recruiting NCT00005799 Not Applicable fludarabine phosphate;cyclosporine;mycophenolate mofetil

Search NIH Clinical Center for Chromophil Renal Cell Carcinoma

Genetic Tests for Chromophil Renal Cell Carcinoma

Anatomical Context for Chromophil Renal Cell Carcinoma

MalaCards organs/tissues related to Chromophil Renal Cell Carcinoma:

41
Kidney, Endothelial, Thyroid, Neutrophil, Colon, Lymph Node

Publications for Chromophil Renal Cell Carcinoma

Articles related to Chromophil Renal Cell Carcinoma:

(show top 50) (show all 131)
# Title Authors Year
1
Differentiation between papillary renal cell carcinoma and fat-poor angiomyolipoma: a preliminary study assessing detection of intratumoral hemorrhage with chemical shift MRI and T2*-weighted gradient echo. ( 29069911 )
2018
2
Three Primary Carcinomas on 18F-FDG PET/CT: Intrahepatic Cholangiocarcinoma, Papillary Renal Cell Carcinoma, and Clear Cell Renal Cell Carcinoma. ( 29561526 )
2018
3
Clear cell papillary renal cell carcinoma - An indolent subtype of renal tumor. ( 30037497 )
2018
4
Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases. ( 30072012 )
2018
5
Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma. ( 30448104 )
2018
6
The molecular characterization and therapeutic strategies of papillary renal cell carcinoma. ( 30474436 )
2018
7
Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres. ( 30507262 )
2018
8
Papillary Renal Cell Carcinoma (PRCC): An Update. ( 30507616 )
2018
9
Primary Extrarenal Type 2 Papillary Renal Cell Carcinoma: A Case Report. ( 30395891 )
2018
10
Cystic Appearance on Imaging Methods (Bosniak III-IV) in Histologically Confirmed Papillary Renal Cell Carcinoma is Mainly Characteristic of Papillary Renal Cell Carcinoma Type 1 and Might Predict a Relatively Indolent Behavior of Papillary Renal Cell Carcinoma. ( 30199877 )
2018
11
A TOP2A-derived cancer panel drives cancer progression in papillary renal cell carcinoma. ( 30214555 )
2018
12
Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan. ( 30224330 )
2018
13
Differentiation of Papillary Renal Cell Carcinoma Subtypes on MRI: Qualitative and Texture Analysis. ( 30240294 )
2018
14
Prevalence of Low-Attenuation Homogeneous Papillary Renal Cell Carcinoma Mimicking Renal Cysts on CT. ( 30240301 )
2018
15
Rare isolated synchronous splenic metastasis in a patient with type II papillary renal cell carcinoma. ( 30264005 )
2018
16
Answer to comment on manuscript "Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients". ( 30022407 )
2018
17
Diagnostic Accuracy of MRI for Detection of Papillary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. ( 30063398 )
2018
18
High proliferation rate and TNM-stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma. ( 30121370 )
2018
19
Type 1 Papillary Renal Cell Carcinoma Presenting as an Infected Benign Renal Cyst: an Uncommon Presentation. ( 29887714 )
2018
20
Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy. ( 29896907 )
2018
21
Can multiphase CT scan distinguish between papillary renal cell carcinoma type 1 and type 2? ( 29932401 )
2018
22
Machine learning models to predict the progression from early to late stages of papillary renal cell carcinoma. ( 29990647 )
2018
23
GCN2 is a potential prognostic biomarker for human papillary renal cell carcinoma. ( 29865032 )
2018
24
Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. ( 29685646 )
2018
25
Re: Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. ( 29704948 )
2018
26
Biphasic papillary renal cell carcinoma is a rare morphological variant with frequent multifocality: a study of 28 cases. ( 29119638 )
2018
27
Ipsilateral synchronous clear and papillary renal cell carcinoma: A case report and review of the literature. ( 29255679 )
2018
28
Fuhrman grading is inappropriate for papillary renal cell carcinoma. ( 29256019 )
2018
29
Papillary renal cell carcinoma with abscess formation: A report of three cases. ( 29343919 )
2018
30
The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. ( 29344091 )
2018
31
Recurrent papillary renal cell carcinoma with concomitant ipsilateral upper urinary tract urothelial carcinoma and metachronous urothelial carcinoma of the bladder. ( 29379740 )
2018
32
Type II papillary renal cell carcinoma with heterotrophic ossification: a case report. ( 29493352 )
2018
33
Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. ( 28592388 )
2018
34
Papillary Renal Cell Carcinoma: A Family Portrait. ( 28642022 )
2018
35
Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy. ( 28753789 )
2018
36
Primary collision tumors of the kidney composed of oncocytoma and papillary renal cell carcinoma: A review. ( 28807339 )
2017
37
Primary collision renal tumor of papillary renal cell carcinoma within an oncocytoma: emergency presentation of a rare entity. ( 30455565 )
2017
38
Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107. ( 30334014 )
2017
39
Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients. ( 28836063 )
2017
40
An integrated analysis for long noncoding RNAs and microRNAs with the mediated competing endogenous RNA network in papillary renal cell carcinoma. ( 28860812 )
2017
41
Toward Biological Subtyping of Papillary Renal Cell Carcinoma With Clinical Implications Through Histologic, Immunohistochemical, and Molecular Analysis. ( 28984673 )
2017
42
Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma. ( 29180625 )
2017
43
Papillary Renal Cell Carcinoma with Tubercular Paraaortic Lymphadenopathy: A Blessing in Disguise. ( 29207723 )
2017
44
Sigmoid Colonic Polyp as Initial Presentation of Metastatic Papillary Renal Cell Carcinoma. ( 29230128 )
2017
45
Chromosomal numerical aberration pattern in papillary renal cell carcinoma: Review article. ( 29454759 )
2017
46
Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma. ( 27324055 )
2017
47
Re: Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4. ( 27417030 )
2017
48
Re: Daniel M. Geynisman. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. Eur Urol 2015;68:912-4. ( 27417031 )
2017
49
Oncocytic Papillary Renal Cell Carcinoma in the Background of Renal Adenomatosis. ( 27494939 )
2017
50
Clinical Significance of Subclassification of Papillary Renal Cell Carcinoma: Comparison of Clinicopathologic Parameters and Oncologic Outcomes Between Papillary Histologic Subtypes 1 and 2 Using the Korean Renal Cell Carcinoma Database. ( 27595560 )
2017

Variations for Chromophil Renal Cell Carcinoma

Expression for Chromophil Renal Cell Carcinoma

Search GEO for disease gene expression data for Chromophil Renal Cell Carcinoma.

Pathways for Chromophil Renal Cell Carcinoma

GO Terms for Chromophil Renal Cell Carcinoma

Sources for Chromophil Renal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....